First Turn Management LLC Purchases Shares of 565,142 Arcus Biosciences, Inc. $RCUS

Posted by Brian Himes on Jun 14th, 2026

First Turn Management LLC purchased a new stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 565,142 shares of the company’s stock, valued at approximately $13,467,000. Arcus Biosciences comprises 1.5% of First Turn Management LLC’s portfolio, making the stock its 29th largest position.

A number of other institutional investors and hedge funds have also bought and sold shares of RCUS. Marshall Wace LLP bought a new position in Arcus Biosciences during the fourth quarter valued at approximately $80,731,000. Vanguard Group Inc. grew its position in Arcus Biosciences by 20.1% during the fourth quarter. Vanguard Group Inc. now owns 7,962,874 shares of the company’s stock valued at $189,755,000 after acquiring an additional 1,333,421 shares during the last quarter. Fisher Asset Management LLC grew its holdings in shares of Arcus Biosciences by 167.4% in the fourth quarter. Fisher Asset Management LLC now owns 1,949,788 shares of the company’s stock worth $46,463,000 after purchasing an additional 1,220,635 shares during the last quarter. State Street Corp grew its holdings in shares of Arcus Biosciences by 34.8% in the fourth quarter. State Street Corp now owns 4,576,969 shares of the company’s stock worth $109,069,000 after purchasing an additional 1,182,115 shares during the last quarter. Finally, Bank of America Corp DE grew its holdings in shares of Arcus Biosciences by 173.5% in the third quarter. Bank of America Corp DE now owns 1,360,781 shares of the company’s stock worth $18,507,000 after purchasing an additional 863,162 shares during the last quarter. 92.89% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Arcus Biosciences

In other news, CAO Alexander Azoy sold 2,562 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $25.77, for a total transaction of $66,022.74. Following the completion of the transaction, the chief accounting officer directly owned 39,581 shares in the company, valued at $1,020,002.37. This trade represents a 6.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Robert C. Goeltz II sold 7,763 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $25.63, for a total value of $198,965.69. Following the transaction, the chief financial officer owned 84,161 shares of the company’s stock, valued at $2,157,046.43. The trade was a 8.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.60% of the stock is owned by company insiders.

Arcus Biosciences Stock Performance

Shares of Arcus Biosciences stock opened at $23.85 on Friday. The company has a current ratio of 4.04, a quick ratio of 4.04 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $3.00 billion, a P/E ratio of -7.50 and a beta of 0.85. The business has a fifty day simple moving average of $24.05 and a two-hundred day simple moving average of $22.92. Arcus Biosciences, Inc. has a 12 month low of $7.91 and a 12 month high of $28.72.

Arcus Biosciences (NYSE:RCUS – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.92) by ($0.10). Arcus Biosciences had a negative net margin of 156.36% and a negative return on equity of 68.97%. The company had revenue of $17.00 million for the quarter, compared to the consensus estimate of $29.49 million. During the same quarter in the previous year, the business earned ($1.14) earnings per share. Arcus Biosciences’s revenue was down 39.3% compared to the same quarter last year. On average, equities analysts forecast that Arcus Biosciences, Inc. will post -3.66 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on RCUS. Truist Financial began coverage on shares of Arcus Biosciences in a report on Monday, May 18th. They issued a “buy” rating and a $35.00 target price on the stock. Citigroup raised their target price on shares of Arcus Biosciences from $44.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Lifesci Capital assumed coverage on Arcus Biosciences in a research note on Thursday, June 4th. They issued an “outperform” rating and a $46.00 price target for the company. Wall Street Zen lowered Arcus Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Arcus Biosciences in a research report on Monday, April 20th. Eight investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Arcus Biosciences presently has an average rating of “Moderate Buy” and a consensus target price of $35.10.

Check Out Our Latest Report on Arcus Biosciences

Arcus Biosciences Profile

(Free Report)

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.